Ted W. Love, MD’s Post

Have you thought about this before? #Excerpt | 'Arjun Gupta and his colleagues coined a term for this concept: time toxicity. “We conceptualize it as the time spent in pursuing, receiving, and recovering from cancer treatments,” says Gupta, a gastrointestinal medical oncologist and health services researcher at the University of Minnesota Medical School in Minneapolis. “It’s not a completely new concept. But I think the way we packaged it and put it out there has put it on the map.” Gupta measures time toxicity as days in contact with the health care system, or “contact days,” regardless of the nature or length of the contact. Measuring time toxicity this way reflects a lesson he’s learned from patients: that even a seemingly short appointment can often become an “all-day affair,” he says. Time toxicity is particularly relevant to patients with advanced, incurable disease, according to Gupta. In these cases, the survival benefit that another line of treatment could bring may be “eaten up” by the time toxicity of the treatment, he says.  It’s up to the patient whether a treatment like that is worth pursuing, says Gupta, but he hopes clinical trials will begin to measure and report time toxicity alongside survival benefits so that patients can make well-informed decisions about their care.' #EndOfLifeCarePlan #EndOfLifeDoula #DeathLiteracy For Graceful Transitions An End-of-Life Doula https://lnkd.in/esatZ5GM

In this Medical Product Outsourcing op-ed by Dr. Jeff Andrews, Vice President of Medical Affairs for Integrated Diagnostic Solutions at BD Life Sciences, notes that unfortunately, the U.S. has fallen behind countries like Denmark, Sweden, the Netherlands, Kenya, Australia and New Zealand, just to name a few, where women are empowered to self-collect for cervical cancer screening. (The FDA has not yet approved self-collection tests for cervical cancer screening in the US). Equally viable and effective, self-collection solutions allow women to collect their own samples without clinician assistance, and in some cases, from the privacy of their homes, foregoing not only the inconvenience but also the added expenses and discomfort often associated with in-person pelvic exams. Self-collection is less invasive. It does not require stirrups and a speculum – just a small swab. The more women can get screened, the more we can detect precancer early and prevent cervical cancer. Let’s work together to address the lack of access to health care that persists around the world. #CervicalCancerAwarenessMonth #SelfCollection #CervicalCancerPrevention #EquitableHealthCare #BDemployee

𝗟𝗘𝗢𝗣𝗔𝗥𝗗 is excited to be featured in 𝗛𝗼𝘀𝗽𝗶𝘁𝗮𝗹 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗘𝘂𝗿𝗼𝗽𝗲! In the article, project coordinator Christophe Duvoux shares his mission to revolutionize organ allocation strategies for end-stage liver disease patients by working with stakeholders across Europe. Discover how AI is set to drive this groundbreaking challenge. Read more: https://lnkd.in/d5SkF7v7 #LEOPARD_AI

In this Medical Product Outsourcing op-ed by Dr. Jeff Andrews, Vice President of Medical Affairs for Integrated Diagnostic Solutions at BD Life Sciences, notes that unfortunately, the U.S. has fallen behind countries like Denmark, Sweden, the Netherlands, Kenya, Australia and New Zealand, just to name a few, where women are empowered to self-collect for cervical cancer screening. (The FDA has not yet approved self-collection tests for cervical cancer screening in the US). Equally viable and effective, self-collection solutions allow women to collect their own samples without clinician assistance, and in some cases, from the privacy of their homes, foregoing not only the inconvenience but also the added expenses and discomfort often associated with in-person pelvic exams. Self-collection is less invasive. It does not require stirrups and a speculum – just a small swab. The more women can get screened, the more we can detect precancer early and prevent cervical cancer. Let’s work together to address the lack of access to health care that persists around the world. #CervicalCancerAwarenessMonth #SelfCollection #CervicalCancerPrevention #EquitableHealthCare #BDemployee

Equally viable and effective, self-collection solutions allow women to collect their own samples without clinician assistance, and in some cases, from the privacy of their homes, foregoing not only the inconvenience but also the added expenses and discomfort often associated with in-person pelvic exams. Self-collection is less invasive. It does not require stirrups and a speculum – just a small swab. In this Medical Product Outsourcing op-ed by Dr. Jeff Andrews, Vice President of Medical Affairs for Integrated Diagnostic Solutions at BD Life Sciences, notes that countries like Denmark, Sweden, the Netherlands, Kenya, Australia and New Zealand, just to name a few, have empowered women to self-collect for cervical cancer screening. (The FDA has not yet approved self-collection tests for cervical cancer screening in the US.) The more women can get screened, the more we can detect precancer early and prevent cervical cancer. Let’s work together to address the lack of access to health care that persists around the world. #CervicalCancerAwarenessMonth #SelfCollection #CervicalCancerPrevention #EquitableHealthCare #BDemployee

🌟 Exciting News for Sickle Cell Treatment! 🌟 We're thrilled to share some incredible news that promises to make a significant difference in the lives of those affected by #SickleCellDisease. The FDA has recently granted approval for two groundbreaking treatments, #Casgevy and #Lyfgenia. 🩸 Casgevy and Lyfgenia represent a new era in sickle cell treatment, offering hope and improved quality of life for patients and their families. These medications have undergone rigorous testing and have demonstrated remarkable effectiveness in managing the symptoms and complications associated with sickle cell disease. 💪 The approval of these treatments by the FDA is a testament to the dedication of countless researchers, healthcare professionals, and organizations working tirelessly to find better solutions for those impacted by sickle cell disease. This momentous occasion not only showcases the advancements in medical science but also underscores our Nations commitment to enhancing the well-being of individuals living with this condition. 🌍 As we move forward, it is our collective responsibility to ensure that these innovative treatments reach those who need them most. We will continue to work closely with healthcare providers, advocacy groups, and communities to raise awareness and facilitate access to Casgevy and Lyfgenia. Let's spread the word and share the hope! Together, we can make a meaningful impact in the lives of individuals affected by sickle cell disease. 💙 #SickleCellTreatment #FDAApproval #MedicalBreakthrough #HopeForSickleCell #C4KCaresAboutSickleCell #NVRDAC #RDAC #NVRDACCaresaboutSCD #Cure4TheKidsFoundation https://lnkd.in/gBE9jEFp

🌟 Exciting News for Sickle Cell Treatment! 🌟 We're thrilled to share some incredible news that promises to make a significant difference in the lives of those affected by #SickleCellDisease. The FDA has recently granted approval for two groundbreaking treatments, #Casgevy and #Lyfgenia. 🩸 Casgevy and Lyfgenia represent a new era in sickle cell treatment, offering hope and improved quality of life for patients and their families. These medications have undergone rigorous testing and have demonstrated remarkable effectiveness in managing the symptoms and complications associated with sickle cell disease. 💪 The approval of these treatments by the FDA is a testament to the dedication of countless researchers, healthcare professionals, and organizations working tirelessly to find better solutions for those impacted by sickle cell disease. This momentous occasion not only showcases the advancements in medical science but also underscores our Nations commitment to enhancing the well-being of individuals living with this condition. 🌍 As we move forward, it is our collective responsibility to ensure that these innovative treatments reach those who need them most. We will continue to work closely with healthcare providers, advocacy groups, and communities to raise awareness and facilitate access to Casgevy and Lyfgenia. Let's spread the word and share the hope! Together, we can make a meaningful impact in the lives of individuals affected by sickle cell disease. 💙 #SickleCellTreatment #FDAApproval #MedicalBreakthrough #HopeForSickleCell #C4KCaresAboutSickleCell #NVRDAC #RDAC #NVRDACCaresaboutSCD #Cure4TheKidsFoundation https://lnkd.in/gBE9jEFp

What are realistic scenarios for long-term efficacy trajectories of amyloid-targeting therapies in Alzheimer’s disease? 🧠📈 Our paper describing a framework for thinking about this has just peen published in Alzheimer’s & Dementia. The timing couldn’t have been better, with encouraging new 3-year follow-up data of one of the amyloid-targeting therapies just being presented at #AAIC24. What do you believe are realistic long-term trajectories? Have a look at the scenarios in our paper and compare to the newly presented data! A big thank you to my coauthors, Jeff Cummings, Alexis Moscoso Rial, Nicolas Villain, and Michael Schöll! https://lnkd.in/dtjsmHfM

February 21st is a date etched in my memory - the anniversary of my brother's passing after a prolonged battle with multiple sclerosis (MS). Tragically, my cousin also succumbed to this terrible disease, and a dear college roommate of mine also fought bravely against MS for the entirety of her adult life. The profound impact of MS on my loved ones underscores the urgent need for effective treatments. Coinciding with this somber anniversary last week, I came across a Nature article that highlights a study offering a beacon of hope - CAR-T therapy for MS treatment. The study details the commencement of the first US trials for this innovative therapy, offering a promising avenue for combating this relentless disease. As I reflect on my brother’s battle with MS and honor his memory, articles like this one offer hope that there could be a future where MS is no longer a source of suffering for so many. I feel privileged to be part of the remarkable scientific community working on new technologies to diagnose and treat diseases, and my gratitude goes out to all the researchers, healthcare professionals, caregivers, and advocates dedicated to finding treatments for MS. The prospect of overcoming the suffering and death caused by MS through scientific advancements, perseverance, and innovation fills me with hope and optimism. You can learn more about this study in this Nature article: https://lnkd.in/ejPe_isN.

Equally viable and effective, self-collection solutions allow women to collect their own samples without clinician assistance, and in some cases, from the privacy of their homes, foregoing not only the inconvenience but also the added expenses and discomfort often associated with in-person pelvic exams. Self-collection is less invasive. It does not require stirrups and a speculum – just a small swab. In this Medical Product Outsourcing op-ed by Dr. Jeff Andrews, Vice President of Medical Affairs for Integrated Diagnostic Solutions at BD Life Sciences, notes that countries like Denmark, Sweden, the Netherlands, Kenya, Australia and New Zealand, just to name a few, have empowered women to self-collect for cervical cancer screening. (The FDA has not yet approved self-collection tests for cervical cancer screening in the US.) The more women can get screened, the more we can detect precancer early and prevent cervical cancer. Let’s work together to address the lack of access to health care that persists around the world. #CervicalCancerAwarenessMonth #SelfCollection #CervicalCancerPrevention #EquitableHealthCare #BDemployee